KRAS and cancer: Three well-characterized cancer hotspots were detected at a MAF of 0.14–0.2% at cycle 1, KRAS G12A with a MAF of 0.19% (BR360030), NRAS Q61L with a MAF of 0.14% (BR360041) and KRAS G12C with a MAF of 0.14% (BR360048), and, collectively, these findings support the sensitive detection of ctDNA mutations by the NGS assay used.